Clinical trials: CART Therapy
Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.
- Trial name
- NCT07874334
- Testing
- GPRC5D CART
- Where
- Israel
- Volunteers
- 160 people
- Sponsor
- Hadassah Medical Organization
Safety, Effective
Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
This is an open, Phase I, investigator-initiated study (IIT) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with moderate or severe active SLE.
- Trial name
- NCT06310811
- Testing
- RD06-04 Cells injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Acute HIV Infection
Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults
The purpose of this study is to assess the ability of the early initiation of cART or cART in combination with autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion to achieve a post-treatment control among…
- Trial name
- NCT02231281
- Testing
- cART(TDF/AZT+3TC+LPV/r), CTL infusion
- Where
- 7 sites in China
- Volunteers
- 65 people
- Sponsor
- Yongtao Sun, MD, PhD
Leukemia, Lymphoma
Cardiovascular Effects of CART Cell Therapy
This is an observational study aiming to prospectively define the rate of occurrence, natural history and progression of cardiac dysfunction in adults, and to identify the patients at high risk of developing cardiovascular…
- Conditions
- Leukemia, Lymphoma, Cardiotoxicity, Risk Factor, Cardiovascular
- Trial name
- CVE-CART (NCT04026737)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ovarian Cancer
Genetically Modified T Cells Against Ovarian Cancer
The primary objectives are to evaluate the safety and efficacy of infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells).
- Trial name
- NCT03184753
- Testing
- OC-IgT cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Acute Lymphoblastic Leukemia ALL
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the…
- Trial name
- NCT06608342
- Testing
- Autologous hematopoietic stem cell transplantation combined with CD19-CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Kidney Transplant, Kidney Failure
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher.
- Conditions
- Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
- Trial name
- NCT06056102
- Testing
- Cyclophosphamide, CART-BCMA, huCART19
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsed/Refractory Multiple Myeloma (MM)
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
- Trial name
- NCT07333430
- Testing
- Naive HBI0101 CAR-T
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Rheumatoid Arthritis
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans.
- Trial name
- Regulate-RA (NCT06201416)
- Testing
- SBT777101
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sonoma Biotherapeutics, Inc.
Leukemia, B-cell
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
This is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of targeted CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19/CD22 positive Relapsed or…
- Trial name
- NCT03614858
- Testing
- CART-19/22
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Ovarian Cancer
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer
- Trial name
- NCT03814447
- Testing
- anti- MESO CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai 6th People's Hospital
Acute Leukemia
CD19-CART Treatment for ALL
This study aims to evaluate the safety and efficacy of a novel CD19-CART in the treatment of refractory or recurrent ALL.
- Trial name
- NCT03232619
- Testing
- CD19 CART
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Bioray Laboratories
Lymphoma, AIDS Related, HIV Infections
A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL
No standard regimen currently exists for the treatment of AIDS-related lymphoma. Based on the encouraging NCI results with DA-EPOCH, the US AIDS Malignancy Consortium is currently administering a phase II randomized protocol…
- Trial name
- CATCH (NCT00799136)
- Testing
- R-EPOCH and cART
- Where
- 2 sites in Canada
- Volunteers
- 6 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
HIV-infected Patients
Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)
The objective was to identify factors associated with the normalization of the CD4/CD8 ratio (>=1) in patients with a history of primary HIV infection (PHI) and long-term combined antiretroviral therapy (cART).
- Trial name
- PRIMIMMUNO (NCT02827227)
- Testing
- lymphocytes immunophenotyping
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Hospices Civils de Lyon
Subjects Who Have Received Lentiviral-based CART-meso Therapy
CART-meso Long-term Follow-up
This is a non-therapeutic, long-term follow-up (LTFU) study of subjects who have received retroviral-based gene therapy products in cancer studies.
- Trial name
- NCT02388828
- Testing
- lentiviral-based CART meso therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania